YAP/Hippo Pathway and Cancer Immunity: It Takes Two to Tango.

Hippo pathway LATS1/2 TAZ YAP cancer immunity immunotherapy

Journal

Biomedicines
ISSN: 2227-9059
Titre abrégé: Biomedicines
Pays: Switzerland
ID NLM: 101691304

Informations de publication

Date de publication:
20 Dec 2021
Historique:
received: 18 09 2021
revised: 09 12 2021
accepted: 15 12 2021
entrez: 24 12 2021
pubmed: 25 12 2021
medline: 25 12 2021
Statut: epublish

Résumé

Hippo pathway with its main molecule YAP is a crucial pathway for development, tissue homeostasis, wound healing, tissue regeneration, and cancer. In this review, we discuss the multiple effects of the YAP/Hippo pathway in the immune system and cancer. We analyzed a series of effects: extracellular vesicles enhanced immunity through inhibition of LATS1/2, ways of modulation of the tumor microenvironment, YAP- and TAZ-mediated upregulation of PDL1, high expression of YAP and PDL1 in EGFR-TKI-resistant cells, enhanced YAP activity in inflammation, and the effect of the Hippo pathway on T cells, B cells, Tregs, macrophages, and myeloid-derived suppressor cells (MDSCs). These pleiotropic effects render the YAP and Hippo pathway a key pathway for exploitation in the future, in order to enhance our immunotherapy treatment strategies in oncology.

Identifiants

pubmed: 34944765
pii: biomedicines9121949
doi: 10.3390/biomedicines9121949
pmc: PMC8698579
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Références

Cell. 2016 Dec 1;167(6):1525-1539.e17
pubmed: 27912060
Cancer Cell. 2019 Jun 10;35(6):868-884.e6
pubmed: 31185211
Cancers (Basel). 2018 Mar 20;10(3):
pubmed: 29558384
Trends Cell Biol. 2017 Mar;27(3):172-188
pubmed: 27979573
Nat Cell Biol. 2008 Dec;10(12):1470-6
pubmed: 19011622
J Biol Chem. 2018 Dec 14;293(50):19290-19302
pubmed: 30333225
FEBS Open Bio. 2015 Jun 22;5:542-9
pubmed: 26199863
Tumour Biol. 2015 Jul;36(7):4889-904
pubmed: 26002574
Cell. 2006 Feb 10;124(3):615-29
pubmed: 16469706
Oncol Rep. 2018 Oct;40(4):2171-2182
pubmed: 30106444
Nat Cell Biol. 2003 Oct;5(10):921-7
pubmed: 14502295
Eur J Immunol. 2010 Dec;40(12):3317-20
pubmed: 21110315
FEBS Lett. 2016 Jan;590(1):68-75
pubmed: 26787462
Nat Cell Biol. 2015 Sep;17(9):1218-27
pubmed: 26258633
J Med Chem. 2018 Jun 28;61(12):5057-5072
pubmed: 29251924
Sci Rep. 2018 Jan 10;8(1):271
pubmed: 29321482
Oncotarget. 2017 Dec 8;9(4):4637-4646
pubmed: 29435131
Cancer Biol Ther. 2013 May;14(5):390-8
pubmed: 23380592
Cell Host Microbe. 2018 Sep 12;24(3):429-438.e6
pubmed: 30212651
Cancer Res. 2018 May 1;78(9):2305-2317
pubmed: 29440144
Proc Natl Acad Sci U S A. 2009 Mar 10;106(10):3794-9
pubmed: 19234131
Genes Dev. 2017 Feb 1;31(3):247-259
pubmed: 28223311
Oncogene. 2014 Mar 13;33(11):1468-74
pubmed: 23542177
Cancer Res. 2018 Mar 15;78(6):1457-1470
pubmed: 29339539
Cancers (Basel). 2018 Mar 28;10(4):
pubmed: 29597279
Cell Rep. 2018 Oct 16;25(3):702-714.e6
pubmed: 30332649
Cancer Discov. 2016 Jan;6(1):80-95
pubmed: 26701088
Biochem Biophys Res Commun. 2017 Sep 16;491(2):493-499
pubmed: 28684311
Proc Natl Acad Sci U S A. 2017 Feb 14;114(7):1643-1648
pubmed: 28130546
Cancer Discov. 2018 Aug;8(8):1026-1043
pubmed: 29907586
Cancer Cell Int. 2020 Oct 12;20:495
pubmed: 33061847
Cancer Res. 1958 Oct;18(9):992-1003
pubmed: 13596939
Genes Dev. 2017 Feb 1;31(3):223-225
pubmed: 28270513
Mol Biol Cell. 2015 Nov 5;26(22):3946-53
pubmed: 26337386
Structure. 2012 Jul 3;20(7):1135-40
pubmed: 22632831
Sci Rep. 2016 Aug 01;6:30483
pubmed: 27476430
Immunology. 2018 Oct;155(2):263-272
pubmed: 29770434
Eur J Immunol. 2015 Apr;45(4):999-1009
pubmed: 25545618
Nano Today. 2015 Jun 1;10(3):397-409
pubmed: 28458718
Mol Cell. 2003 Jan;11(1):11-23
pubmed: 12535517
Mol Cell. 2015 Oct 15;60(2):328-37
pubmed: 26439301
Cancer Res. 2010 Dec 1;70(23):9621-30
pubmed: 21098712
J Hematol Oncol. 2017 Feb 28;10(1):60
pubmed: 28241877
Biomaterials. 2018 Apr;161:164-178
pubmed: 29421553
Nat Immunol. 2017 Jul;18(7):800-812
pubmed: 28504697
J Biol Chem. 2012 Jun 22;287(26):22089-98
pubmed: 22544757
Biochem Biophys Res Commun. 2016 May 20;474(1):154-160
pubmed: 27105908
Cancer Lett. 2017 Aug 28;402:61-70
pubmed: 28576749
Cancer Cell. 2014 Feb 10;25(2):166-80
pubmed: 24525233
Oncotarget. 2018 Feb 6;9(18):14175-14192
pubmed: 29581836
Immunity. 2012 Mar 23;36(3):374-87
pubmed: 22425248
PLoS Genet. 2015 Aug 21;11(8):e1005465
pubmed: 26295846
J Am Chem Soc. 2019 Mar 13;141(10):4257-4263
pubmed: 30601664
Oncogene. 2017 Jan 26;36(4):534-545
pubmed: 27321186
Theranostics. 2020 Feb 18;10(8):3622-3635
pubmed: 32206112
Cell Physiol Biochem. 2017;41(3):1189-1198
pubmed: 28472799
J Transl Med. 2015 Feb 01;13:47
pubmed: 25638150
Nat Rev Cancer. 2013 Oct;13(10):739-52
pubmed: 24060865
Cancer Res. 2007 Jan 15;67(2):585-92
pubmed: 17234767
Nat Cell Biol. 2014 Apr;16(4):357-66
pubmed: 24658687
Front Immunol. 2020 Aug 04;11:1473
pubmed: 32849504
Proc Natl Acad Sci U S A. 2001 Jul 17;98(15):8554-9
pubmed: 11438690
J Cell Mol Med. 2018 Jun;22(6):3139-3148
pubmed: 29575535
Oncoimmunology. 2016 Mar 28;5(6):e1160187
pubmed: 27471633
Blood Adv. 2016 Dec 14;1(3):219-230
pubmed: 29296937
J Immunol. 2009 Sep 15;183(6):3720-30
pubmed: 19692638
Cell Rep. 2015 Jul 14;12(2):244-57
pubmed: 26146082
Nat Med. 2014 Jun;20(6):599-606
pubmed: 24813251
J Biol Chem. 2013 Apr 12;288(15):10849-59
pubmed: 23439645
Front Immunol. 2014 Jun 17;5:276
pubmed: 24987392
Blood Adv. 2018 Sep 25;2(18):2282-2295
pubmed: 30213787
J Clin Invest. 2012 Nov;122(11):4094-104
pubmed: 23064360
Nat Cell Biol. 2008 May;10(5):619-24
pubmed: 18425114
J Exp Clin Cancer Res. 2019 Feb 8;38(1):62
pubmed: 30736829
Genes Dev. 2012 Jun 15;26(12):1300-5
pubmed: 22677547
Oncogene. 2017 Mar 2;36(9):1232-1244
pubmed: 27546622
J Transl Med. 2010 Feb 08;8:13
pubmed: 20141634
Front Immunol. 2020 May 06;11:733
pubmed: 32435241
PLoS One. 2012;7(10):e47045
pubmed: 23077543
Genes Dev. 2017 Jun 1;31(11):1109-1121
pubmed: 28698296
Nat Rev Cancer. 2004 Jan;4(1):71-8
pubmed: 14708027
Mol Cell. 2008 Feb 15;29(3):350-61
pubmed: 18280240
Gut. 2018 Sep;67(9):1692-1703
pubmed: 28866620
Cancer Immunol Res. 2018 Mar;6(3):255-266
pubmed: 29382670
Immune Netw. 2020 Oct 19;20(5):e36
pubmed: 33163244

Auteurs

Dimitrios Matthaios (D)

Department of Medical Oncology, Rhodes General Hospital, 85100 Rhodes, Greece.

Maria Tolia (M)

Department of Radiotherapy, School of Medicine, University of Crete, 71500 Heraklion, Greece.

Davide Mauri (D)

Department of Medical Oncology, University of Ιoannina, 45110 Ιoannina, Greece.

Konstantinos Kamposioras (K)

Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester M20 4BX, UK.

Michalis Karamouzis (M)

Molecular Oncology Unit, Department of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece.

Classifications MeSH